Our Top Stories
Research
- ATHN Transcends
As ATHN’s flagship observational study, ATHN Transcends streamlines data collection and administration for our ATHN Affiliates, while supporting investigators in the exploration of scientifically meaningful questions to determine the safety, effectiveness, and practice of therapies used in the treatment of hematologic disorders. ATHN Transcends is open at treatment centers across the country—and it’s growing. - SOC 2 Type II Compliance
At ATHN, we know the importance of data security and privacy—for us and for our ATHN Affiliates and other partners. We’re proud to receive SOC 2 Type II compliance in all five trust principles: security, availability, processing integrity, confidentiality, and privacy.
National Projects

- ATHN Data Quality Counts
This competitive award is supported by The Hemophilia Alliance, The Alliance Pharmacy, and Indiana Hemophilia & Thrombosis Center and provides funding to build data management capacity and enrich the ATHNdataset.
News
- 20 Years of Data Innovation
In 2026, ATHN is celebrating 20 years of progress, powered by data and driven by purpose. Since we began in 2006, we’ve worked with our ATHN Affiliates and other collaborating partners to secure data, advance knowledge, and transform care for those affected by blood disorders—and together we’ve made a real impact. Our year-long 20th anniversary celebration will culminate at ATHN Data Summit 2026 in New Orleans, October 21-22, 2026—and we invite you to join us. - Office of Public Health Initiatives
The ATHN Office of Public Health Initiatives (OPHI) aims to leverage ATHN’s capabilities to support medically underserved populations by strengthening our partnerships throughout the rare disorders community. We’re working to establish a Health Equity Program, expand ATHN’s focus on sickle cell disease, and more.
Upcoming Events
- 11-14
JUN, 2026 - EHA2026 Congress
Stockholm, Sweden
- 11-15
JUL, 2026 - International Society on Thrombosis and Haemostasis
Paris, France
- 21-22
OCT, 2026 - ATHN Data Summit 2026
New Orleans, LA
Featured Publications
Human Leukocyte Antigen Alleles Associated with Inhibitor Development in Severe Hemophilia A: Analysis of the “My Life, Our Future” Hemophilia A Cohort published in Journal of Thrombosis and Haemostasis, February 2026. Read the articleF8 Variants and Inhibitor Development in a Multiethnic Cohort of Nonsevere Haemophilia A published in the Haemophilia, November 2025. Read the article
Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study published in Haemophilia, November 2025. Read the article



